Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 13/20 | 0.83 |
| ▸ | ESR1 | P03372 | 12/20 | 0.83 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | DRD1 | P21728 | 3/20 | 0.47 |
| ▸ | DRD5 | P21918 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8176145 | 0.91 | ESR2 (1.00) | ESR2ESR1DRD2DRD1DRD5 | |
| SCHEMBL2585109 | 0.86 | ESR1 (0.62) | ESR2ESR1ABHD6HDAC6 | |
| SCHEMBL373718 | 0.83 | ESR1 (0.58) | ESR2ESR1ABHD6HDAC6CA1 | |
| SCHEMBL7849236 | 0.83 | ESR2 (0.58) | ESR2ESR1ABHD6HDAC6CA1 | |
| SCHEMBL27176737 | 0.83 | ESR1 (0.58) | ESR2ESR1ABHD6HDAC6 | |
| SCHEMBL566629 | 0.83 | ESR1 (0.58) | ESR2ESR1ABHD6HDAC6CA1 | |
| SCHEMBL1787936 | 0.83 | ABHD6 (0.60) | ESR2ESR1ABHD6HDAC6 | |
| SCHEMBL7423258 | 0.81 | ESR1 (0.57) | ESR2ESR1ABHD6HDAC6 | |
| SCHEMBL506139 | 0.81 | ESR1 (0.59) | ESR2ESR1ABHD6 | |
| SCHEMBL1790256 | 0.80 | ESR1 (0.56) | ESR2ESR1ABHD6HDAC6CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2938345-B1 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING CO (US) | 2018-08-22 | — | — | EP | disclosed |
| US-9284277-B2 | Benzazepines as serotonin 5-HT2C receptor ligands and uses thereof | ABT HOLDING COMPANY (US) | 2016-03-15 | — | — | US | disclosed |
| US-9284277-B2 | Benzazepines as serotonin 5-HT2C receptor ligands and uses thereof | ABT HOLDING COMPANY (US) | 2016-03-15 | — | — | US | disclosed |
| EP-2610258-B1 | Substituted piperidino dihydrothieno pyrimidines | BOEHRINGER INGELHEIM INT (DE) | 2014-08-27 | — | — | EP | disclosed |
| EP-2610258-B1 | Substituted piperidino dihydrothieno pyrimidines | BOEHRINGER INGELHEIM INT (DE) | 2014-08-27 | — | — | EP | disclosed |
| US-20140194411-A1 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194411-A1 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194411-A1 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2014100815-A2 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-06-26 | — | — | WO | disclosed |
| US-8754073-B2 | Substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | BLANCO-PILLADO MARIA-JESUS | 2008-10-30 | — | — | US | disclosed |
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | BLANCO-PILLADO MARIA-JESUS | 2008-10-30 | — | — | US | disclosed |
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | BLANCO-PILLADO MARIA-JESUS | 2008-10-30 | — | — | US | disclosed |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2008-10-16 | — | — | US | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269296-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRL1 | ESR2 128/4885ESR1 125/4885DRD2 169/4885 |
| US-20140194411-A1 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | HTR2C, HTR2A, HTR5A | ESR2 489/4885ESR1 772/4885DRD2 24/4885 |
| US-20080255152-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRL1 | ESR2 130/4885ESR1 128/4885DRD2 184/4885 |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | OPRM1, OPRL1, OPRD1 | ESR2 127/4885ESR1 141/4885DRD2 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.